By
The drug has already been successfully tested in animal studies.
if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[728,90],’scitechdaily_com-box-3′,’ezslot_6′,102,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-box-3-0’);
Scientists develop a new drug candidate to treat diabetes.
A novel hormone combination has been created by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk for the potential treatment of type 2 diabetes in the future. The researchers combined the blood sugar-lowering actions of the medications tesaglitazar and GLP-1 (Glucagon-like peptide-1) to create a new and extremely effective drug.
The benefit of combining Tesaglitazar with GLP-1 is that the Tesaglitazar only penetrates the tissue with GLP-1 receptors. This increases the effects on sugar metabolism while lessening the side effects of tesaglitazar. Scientists have already successfully tested the new drug in animal studies. The study was recently published in the journal Nature Metabolism.
if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[580,400],’scitechdaily_com-medrectangle-3′,’ezslot_7′,110,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-medrectangle-3-0’);
Tesaglitazar enhances glucose and fat metabolism in type 2 diabetic patients. It increases insulin sensitivity by acting on two receptors inside the cell nucleus. This was demonstrated in phase 3 clinical trials. However, tesaglitazar has side effects such as kidney damage.
catch(error){}
The new drug candidate (GLP-1/tesaglitazar) enhanced improvements of body weight, food intake, and glucose metabolism relative to the GLP-1 or tesaglitazar alone in obese male mice. Credit: Helmholtz Munich
However, in order to utilize the drug therapeutically, the researchers employed a trick: they biochemically combined tesaglitazar with the gastrointestinal hormone GLP-1. As a result, the combined drug can only work on cells and tissues that have GLP-1 receptors.
if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[728,90],’scitechdaily_com-medrectangle-4′,’ezslot_9′,111,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-medrectangle-4-0’);
“This trick enabled us to combine the blood sugar-reducing effects of GLP-1 and tesaglitazar into a single highly effective molecule while keeping tesaglitazar away from tissues that it could damage,” explains PD Dr. Timo Müller, corresponding author, director of the Institute of Diabetes and Obesity, and scientist at DZD.
The new drug improves glucose tolerance and sugar metabolism
The new drug has already been successfully tested in animal studies: “The sugar metabolism of obese and diabetic male mice improved to a far greater extent compared with treatment using only the GLP-1 hormone or tesaglitazar alone – and with no damaging adverse effects to the liver or kidney,” says Professor Kerstin Stemmer, one of the lead authors of the study.
The substance was particularly effective in increasing glucose tolerance levels. Only minimal doses of the new drug were required to achieve sustainable improvement of glucose metabolism.
“This drug has great potential for the acute treatment of elevated blood sugar levels associated with type 2 diabetes,” says Aaron Novikoff, another lead author of the study.
if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[300,250],’scitechdaily_com-box-4′,’ezslot_11′,112,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-box-4-0’);
The researchers now want to investigate whether this drug also has the potential to treat humans with type 2 diabetes and whether the efficacy of this new combination therapy can be optimized further using biochemical modifications.
Background:
The team comprised of Professor Dr. Matthias Tschöp (scientific director of Helmholtz Munich), PD Dr. Timo Müller, Richard DiMarchi, Ph.D. (Indiana University), and Dr. Brian Finan (Novo Nordisk) has been working for many years on new drug candidates for the treatment of type 2 diabetes and obesity. Poly-agonists simultaneously mimic the effects of various hormones. Clinical trials have shown that some poly-agonists are exceptionally promising in the treatment of obesity and type 2 diabetes and are already in phase 2 and phase 3 trials.
This year in the USA the first dual agonist drug for the treatment of type 2 diabetes was approved. The drug combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists that mimic the effects of the intestinal hormones GLP-1 and GIP.
Reference: “GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice” by Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Baugé, Jonathan E. Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J. Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M. Hofmann, Patrick J. Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A. Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, and Timo D. Müller, 22 August 2022, Nature Metabolism.
DOI: 10.1038/s42255-022-00617-6
if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[728,90],’scitechdaily_com-leader-4′,’ezslot_23′,187,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-leader-4-0’);
The drug has already been successfully tested in animal studies.
A novel hormone combination has been created by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk for the potential treatment of type 2 diabetes in the future. The researchers combined the blood sugar-lowering actions of the medications tesaglitazar and GLP-1 (Glucagon-like peptide-1) to create a new and extremely effective drug.
The benefit of combining Tesaglitazar with GLP-1 is that the Tesaglitazar only penetrates the tissue with GLP-1 receptors. This increases the effects on sugar metabolism while lessening the side effects of tesaglitazar. Scientists have already successfully tested the new drug in animal studies. The study was recently published in the journal Nature Metabolism.
Tesaglitazar enhances glucose and fat metabolism in type 2 diabetic patients. It increases insulin sensitivity by acting on two receptors inside the cell nucleus. This was demonstrated in phase 3 clinical trials. However, tesaglitazar has side effects such as kidney damage.
catch(error){}
The new drug candidate (GLP-1/tesaglitazar) enhanced improvements of body weight, food intake, and glucose metabolism relative to the GLP-1 or tesaglitazar alone in obese male mice. Credit: Helmholtz Munich
The new drug candidate (GLP-1/tesaglitazar) enhanced improvements of body weight, food intake, and glucose metabolism relative to the GLP-1 or tesaglitazar alone in obese male mice. Credit: Helmholtz Munich
However, in order to utilize the drug therapeutically, the researchers employed a trick: they biochemically combined tesaglitazar with the gastrointestinal hormone GLP-1. As a result, the combined drug can only work on cells and tissues that have GLP-1 receptors.
“This trick enabled us to combine the blood sugar-reducing effects of GLP-1 and tesaglitazar into a single highly effective molecule while keeping tesaglitazar away from tissues that it could damage,” explains PD Dr. Timo Müller, corresponding author, director of the Institute of Diabetes and Obesity, and scientist at DZD.
The new drug improves glucose tolerance and sugar metabolism
The new drug has already been successfully tested in animal studies: “The sugar metabolism of obese and diabetic male mice improved to a far greater extent compared with treatment using only the GLP-1 hormone or tesaglitazar alone – and with no damaging adverse effects to the liver or kidney,” says Professor Kerstin Stemmer, one of the lead authors of the study.
The substance was particularly effective in increasing glucose tolerance levels. Only minimal doses of the new drug were required to achieve sustainable improvement of glucose metabolism.
“This drug has great potential for the acute treatment of elevated blood sugar levels associated with type 2 diabetes,” says Aaron Novikoff, another lead author of the study.
The researchers now want to investigate whether this drug also has the potential to treat humans with type 2 diabetes and whether the efficacy of this new combination therapy can be optimized further using biochemical modifications.
Background:
The team comprised of Professor Dr. Matthias Tschöp (scientific director of Helmholtz Munich), PD Dr. Timo Müller, Richard DiMarchi, Ph.D. (Indiana University), and Dr. Brian Finan (Novo Nordisk) has been working for many years on new drug candidates for the treatment of type 2 diabetes and obesity. Poly-agonists simultaneously mimic the effects of various hormones. Clinical trials have shown that some poly-agonists are exceptionally promising in the treatment of obesity and type 2 diabetes and are already in phase 2 and phase 3 trials.
This year in the USA the first dual agonist drug for the treatment of type 2 diabetes was approved. The drug combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists that mimic the effects of the intestinal hormones GLP-1 and GIP.
Reference: “GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice” by Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Baugé, Jonathan E. Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J. Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M. Hofmann, Patrick J. Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A. Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, and Timo D. Müller, 22 August 2022, Nature Metabolism.
DOI: 10.1038/s42255-022-00617-6
Health
Obesity / Type 2 Diabetes Changes Cell Response to Glucose, Uses Slower Metabolic Path
Long-Standing Enigma Finally Cracked – Link Discovered Between High Blood Pressure and Diabetes
The Obesity Society Issues New Position Statement on COVID-19 Vaccines
Medication Shows Benefits Treating Type 1 Diabetes – Delayed Disease Progression, Lowered Insulin Requirements
New Game-Changing Obesity Drug Dramatically Reduces Risk of Type 2 Diabetes
Engineered Insulin Stays in Bloodstream, Offers Better Diabetes Control
Weight Loss of 15% or More Should Be Central Focus of Type 2 Diabetes Management
Cockroach Courtship and Mating: Sugar Aversion Hampers Cockroach Coupling
I would like to get updated on this drug please
Thank you
I would also like an update on this medication.im a diabetic
I’m so excited about this. Hope it gets to patients sooner rather than later. Thankyou to all the people involved in working on this. You will be changing people’s lives!!!!!!
So they combined two known drugs into one. A lot like taking the two drugs separately. Wake me when the excitement dies down.
U r not gonna wanna eat dat egg 🍳
I would like information on any medication to help eliminate type 2 diabetes and weight loss
I really appreciate it can be helpful to my type 2 diabetes and weight loss hoping for the best part of a now drug thank you for This information
i would like and update on new dibectdrug.
Husband is skinny diabetic and dependent on insulin, any updates on drug info, trials, or ways to help him gain weight without carbs or affecting his heart health would be appreciated
Wouldn’t a better solution be to eat without spiking blood glucose (and insulin). After all a key problem with diabetics (and many with metabolic syndrome) is hyperinsulinemia. Dealing solely with blood glucose seems to be missing the mark altogether.
Hope it soon come to Indian patient use
I am a type 2 diabetic
Sure everybody waits for any new updates on any drug that says a hope in diabetes. Pl wait till the drug proved in the market as it says there’s a side effect. Any drug differs action/side effects patient to patient. Prffer older drugs particularly for bp and diabetics with proper timings and dieting rather than running for new drugs. Recently I had been to a tour which forced me to walk extensively with improper food and sugars. Even I had to stop insulin as it’s inconvenient. But to my surprise, after 13 days it shows 8.4 which should have been otherwise between 12 to 15.with the age of around 70yrs.
My family we are struggling with type 2diabetes and many people here in Kenya, I have hope that it can reach the poor countries and help. Hope this is the beginning of freedom from the prison of type 2diabates.
I would hope this drug will be available to me. I’ve tried just about everything to lose weight but have failed. Please help me.
I hope that this drug would be available soon.
I need to know more about the drugs, am diabetic for 15years now.
Email address is optional. If provided, your email will not be published or shared.
document.getElementById(“ak_js_1”).setAttribute(“value”,(new Date()).getTime());
SciTechDaily: Home of the best science and technology news since 1998. Keep up with the latest scitech news via email or social media.
> Subscribe Free to Email Digest
October 21, 2022
What Makes You at Risk for Alzheimer’s? Researchers Have New Insight
Scientists shed new light on the genetic and molecular machinery that predispose individuals to Alzheimer’s disease. Human microglia are immune cells that reside in the…
Scientists shed new light on the genetic and molecular machinery that predispose individuals to Alzheimer’s disease. Human microglia are immune cells that reside in the…
October 21, 2022
New Research Suggests That Obesity Is a Neurodevelopmental Disorder
October 21, 2022
Wearing a Mask Can Change Your Behavior
October 21, 2022
DART Asteroid Impact Aftermath: Hubble Spots Unexpected Twin Tails in “Stunning Surprise”
October 20, 2022
Eating at Night Linked to Depression and Anxiety-Like Moods
October 20, 2022
New Pill Replicates Exercise and Strengthens Muscle
October 20, 2022
New Study Indicates North Atlantic Is Close to a “Tipping Point”
October 20, 2022
Adult Brain Structure Is Not Fixed: Scientists Discover Depression Treatment Increases Brain Connectivity
Copyright © 1998 – 2022 SciTechDaily. All Rights Reserved.